These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36015287)

  • 1. Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1.
    Choe EJ; Lee CH; Bae JH; Park JM; Park SS; Baek MC
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1.
    Park SS; Kim JI; Lee CH; Bae JH; Park JM; Choe EJ; Baek MC
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular vesicle-mediated immunoregulation in cancer.
    Yamamoto T; Yamamoto Y; Ochiya T
    Int J Hematol; 2023 May; 117(5):640-646. PubMed ID: 35951282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model.
    Veerman RE; Akpinar GG; Offens A; Steiner L; Larssen P; Lundqvist A; Karlsson MCI; Gabrielsson S
    Cancer Immunol Res; 2023 Feb; 11(2):217-227. PubMed ID: 36546872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
    Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
    Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM
    World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
    Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR.
    Liu X; Yin M; Dong J; Mao G; Min W; Kuang Z; Yang P; Liu L; Zhang N; Deng H
    Acta Pharm Sin B; 2021 Oct; 11(10):3134-3149. PubMed ID: 34745852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABA/baclofen stabilizes PD-L1 and enhances immunotherapy of breast cancer.
    Sun X; Lin M; Tian Z; Ma Y; Lv L
    Heliyon; 2024 Apr; 10(7):e28600. PubMed ID: 38601585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GC-Derived EVs Enriched with MicroRNA-675-3p Contribute to the MAPK/PD-L1-Mediated Tumor Immune Escape by Targeting CXXC4.
    Li P; Luo X; Xie Y; Li P; Hu F; Chu J; Chen X; Song W; Wang A; Tian G; Gu X
    Mol Ther Nucleic Acids; 2020 Dec; 22():615-626. PubMed ID: 33230461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity.
    Shi Y; Zhang J; Mao Z; Jiang H; Liu W; Shi H; Ji R; Xu W; Qian H; Zhang X
    Front Oncol; 2020; 10():629. PubMed ID: 32477934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of Type 1 Diabetes.
    Rao C; Cater DT; Roy S; Xu J; Olivera AG; Evans-Molina C; Piganelli JD; Eizirik DL; Mirmira RG; Sims EK
    bioRxiv; 2024 Sep; ():. PubMed ID: 39345410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy
    Zhou X; Zou L; Liao H; Luo J; Yang T; Wu J; Chen W; Wu K; Cen S; Lv D; Shu F; Yang Y; Li C; Li B; Mao X
    Acta Pharm Sin B; 2022 Feb; 12(2):692-707. PubMed ID: 35256940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
    Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
    Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
    Wu B; Sun X; Gupta HB; Yuan B; Li J; Ge F; Chiang HC; Zhang X; Zhang C; Zhang D; Yang J; Hu Y; Curiel TJ; Li R
    Oncoimmunology; 2018; 7(11):e1500107. PubMed ID: 30393583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1.
    Jung MY; Aibaidula A; Brown DA; Himes BT; Cumba Garcia LM; Parney IF
    Neurooncol Adv; 2022; 4(1):vdac017. PubMed ID: 35990703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 20. Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC.
    Shukuya T; Ghai V; Amann JM; Okimoto T; Shilo K; Kim TK; Wang K; Carbone DP
    J Thorac Oncol; 2020 Nov; 15(11):1773-1781. PubMed ID: 32565389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.